Interferon regulatory factor 3 (IRF3), which often suggests a poor prognosis for CRC patients, is an agonist of YAP1 and a target for tumor therapy (Chen YJ et al., 2021). The gene discussed is IRF3; the disease is colorectal carcinoma.